Key takeaways
- The 2.5 mg dose is a tolerability dose, not a treatment dose; the label uses it for four weeks to let the gut adapt before 5 mg.
- Nausea affects roughly a quarter to a third of patients across SURMOUNT-1 doses and peaks in the first days after each dose increase; it is usually mild to moderate and usually fades within weeks.
- Small, low-fat, slowly eaten meals, stopping at first fullness, and adequate fluids are the interventions that reduce first-month gastrointestinal symptoms most; the [protein and water tool](/tools/glp-1-protein-water/) sets targets.
- Mean weight loss by week four in the trials was about 2-4%; most of the effect comes after reaching 10-15 mg, so a small first-month number is expected.
- Severe or persistent abdominal pain radiating to the back, vomiting that prevents fluids for 24 hours, signs of allergic reaction, or a neck lump warrant immediate contact with a clinician.
What the first dose is for
The 2.5 mg starting dose of tirzepatide is not intended to produce much weight loss. The Zepbound label describes it as a dose "for treatment initiation" and specifies four weeks at 2.5 mg before increasing, because the gastrointestinal effects of GLP-1 and GIP receptor activation are dose-dependent and the gut adapts with exposure. In SURMOUNT-1, all participants started at 2.5 mg, and the trial's adverse-event data show that nausea, vomiting and diarrhea clustered in the days following each escalation and declined between escalations. The first month is the first of those adaptation periods, and it is usually the gentlest.
Patients who are new to GLP-1s sometimes ask on sales calls whether they can try one month before committing, specifically because of side effects. That is a reasonable plan, and knowing what the month looks like makes the decision easier.
Week 1
You inject 2.5 mg once, subcutaneously, in the abdomen, thigh or upper arm, on a day you will keep every week. For compounded tirzepatide in a vial, you draw the dose with an insulin syringe; confirm the units for your vial's concentration with the dose calculator and the pharmacy's instructions before the first injection, because this is the moment when unit errors happen. Rotate injection sites week to week.
Tirzepatide reaches peak concentration in 8 to 72 hours and its effect on appetite is noticeable for many patients within the first two or three days. The most common early experiences are reduced hunger, feeling full sooner, and, in a minority, nausea, usually mild. Some patients notice fatigue or mild headache, which can reflect eating and drinking less rather than the drug directly. Injection-site redness or a small bump is common and resolves.
The single most useful habit to establish in week one is eating smaller portions slowly and stopping at the first sign of fullness. Tirzepatide slows gastric emptying; a normal-sized meal eaten at normal speed sits in the stomach and produces nausea. Low-fat foods empty faster than high-fat ones. Fluids between meals rather than with them help.
Week 2
The second dose arrives while the first is still partly on board (the half-life is about five days), so exposure rises slightly. For most patients week two is similar to week one or a little easier as the gut adapts; for a few, nausea or constipation becomes more noticeable. Constipation is under-discussed: slowed motility plus reduced intake produces it in about 17% of SURMOUNT-1 participants at 5 mg. Fluids, fiber and movement help; a stool softener is reasonable if needed. Diarrhea affects a similar proportion and usually resolves.
Weight may fall a pound or two, or several, mostly from reduced intake and some fluid. It may also not move much yet. Both are normal.
Week 3
By the third dose most patients have settled into a pattern. The appetite effect is stable; nausea, if present, has usually eased. This is a good week to attend to protein and fluids, because appetite suppression makes both easy to under-consume, and under-consuming both is the most common cause of first-month fatigue and hair shedding later. The protein and water tool gives targets; the calorie calculator shows the floor below which intake should not fall.
Alcohol tolerance drops for many patients; a drink that was fine before may cause nausea or feel stronger. Reflux can appear with slowed emptying; smaller evening meals and not lying down after eating help.
Week 4 and the first escalation
The fourth dose completes the initiation period. Trial averages for weight change at four weeks were roughly 2 to 4% of body weight; for a 220-pound patient that is 4 to 9 pounds. Individual results vary from nothing to considerably more, and a small number is not a sign the medication will not work — SURMOUNT-1's 20.9% mean at 15 mg was reached at 72 weeks, and most of it came after month four.
Around week four the clinician decides whether to increase to 5 mg. If the first month has been comfortable, the label's schedule proceeds. If nausea has been troublesome, staying at 2.5 mg for another two to four weeks is within the label and common in telehealth practice. Each subsequent escalation (5, 7.5, 10, 12.5, 15 mg) tends to bring a few days of renewed gastrointestinal symptoms that fade; the pattern learned in the first month repeats. Our timeline tool shows the shape of the year.
What is expected and what is not
Expected: mild to moderate nausea, especially after dose changes; constipation or diarrhea; reduced appetite; early fullness; mild fatigue; injection-site reactions; belching or reflux; small early weight changes.
Not expected, and worth a call: vomiting that prevents you keeping fluids down for 24 hours (dehydration is the route to the acute kidney injury in the labeling); severe, persistent abdominal pain, particularly radiating to the back, with or without vomiting (pancreatitis must be excluded); right upper abdominal pain, fever or yellowing of the eyes (gallbladder); hives, facial swelling or difficulty breathing (hypersensitivity); a lump or swelling in the neck, hoarseness or trouble swallowing (the thyroid warning); symptoms of hypoglycemia if you take insulin or a sulfonylurea; and new or worsening depression or thoughts of self-harm, which the labeling asks clinicians to monitor. The important safety information page has the full list.
Practical notes for month one
Tell any surgeon or anesthesiologist you are on tirzepatide; guidance asks for a hold before procedures because of delayed gastric emptying. If you miss a dose, take it within four days; if more than four days have passed, skip it and resume on schedule. Keep the vial refrigerated per the label. Keep your provider informed: telehealth providers that include 24/7 support or clinician messaging in the price — NexLife's plans do — are worth using in month one, when questions are most frequent.
The decision at the end of the month
Most patients who complete the first month continue; in SURMOUNT-1, discontinuation for adverse events over the full 72 weeks was 4 to 7%. If you started on a month-to-month plan to test tolerability, the end of month one is when moving to a term plan makes financial sense — NexLife's 12-month rate is $30 per month below its month-to-month rate — and the cancellation guide explains what to check before committing. If the month went badly, the switching guide and the semaglutide reference cover the alternatives: a slower titration, or the other molecule.
Frequently asked questions
How much weight will I lose in the first month on tirzepatide?
Trial averages were about 2-4% of body weight by week four at 2.5 mg, with wide individual variation. The starting dose is for tolerability; most of the loss comes at 10-15 mg from month four onward.
How long does nausea last on tirzepatide?
In the trials, nausea was most common in the days after each dose increase and declined over the following weeks. For most patients first-month nausea is mild to moderate and settles within two to three weeks; it can recur briefly at each escalation.
What should I eat during the first month on tirzepatide?
Smaller portions, lower fat, eaten slowly, stopping at first fullness. Prioritize protein (about 1.2-1.6 g per kg per day) and fluids. Avoid large, greasy or very sweet meals, which are the commonest nausea triggers.
When should I call my clinician in the first month?
For persistent vomiting or inability to keep fluids down for 24 hours, severe abdominal pain (especially radiating to the back), signs of an allergic reaction, a lump or swelling in the neck, symptoms of low blood sugar if you take diabetes medication, or any symptom that worries you.
Sources
- Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205-216, supplementary appendix adverse event timing
- Zepbound (tirzepatide) prescribing information, sections 2, 5 and 6
- Wharton S et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity. Postgrad Med 2022;134:14-19
- American Society of Anesthesiologists, consensus-based guidance on preoperative management of GLP-1 receptor agonists (2023, updated 2024)
Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.